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Abstract
Rationale: The maintenance of peripheral muscle mass may be compromised in chronic obstructive pulmonary disease
(COPD) due to premature cellular senescence and exhaustion of the regenerative potential of the muscles.
Methods: Vastus lateralis biopsies were obtained from patients with COPD (n=16) and healthy subjects (n=7). Satellite cell
number and the proportion of central nuclei, as a marker of muscle regenerative events, were assessed on cryosections.
Telomere lengths, used as a marker of cellular senescence, were determined using Southern blot analyses.
Results: Central nuclei proportion was significantly higher in patients with COPD with a preserved muscle mass compared
to controls and patients with COPD with muscle atrophy (p,0.001). In COPD, maximal telomere length was significantly
decreased compared to controls (p,0.05). Similarly, minimal telomere length was significantly reduced in GOLD III–IV
patients with muscle atrophy compared to controls (p,0.005). Minimal, mean and maximum telomere lengths correlated
with mid-thigh muscle cross-sectional area (MTCSA) (R=0.523, p=0.005; R=0.435, p=0.019 and R=0.491, p=0.009,
respectively).
Conclusions: Evidence of increased regenerative events was seen in GOLD III–IV patients with preserved muscle mass.
Shortening of telomeres in GOLD III–IV patients with muscle atrophy is consistent with an increased number of senescent
satellite cells and an exhausted muscle regenerative capacity, compromising the maintenance of muscle mass in these
individuals.
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Introduction
Skeletal muscle atrophy is observed in a variety of acute and
chronic conditions [1–5] including chronic obstructive pulmonary
disease (COPD) [6]. In COPD, the unintentional loss of muscle
mass has a significant impact on quality of life [7] and is associated
with premature death [8]. Many biochemical factors have been
proposed to initiate and promote the development of skeletal
muscle atrophy in COPD [9]. Satellite cell senescence impairing
muscle regeneration capacity could be involved in this process
[10]. To date, no studies have investigated the prevalence of
satellite cell senescence in the context of muscle mass maintenance
in COPD.
Satellite cells represent the primary source of myogenic
precursor cells contributing to the processes of muscle mass
maintenance, hypertrophy and repair after birth [11]. Under their
quiescent state, satellite cells are found between the plasmalemma
and the basal lamina on the surface of muscle fibre [12]. Upon
activation, they proliferate into myoblasts and migrate to the
requested site (reviewed by Charge [11]). Newly formed myoblasts
will exit the cell cycle, differentiate into myotubes and fuse to an
injured myofibre [13]. Newly formed myofibres exhibit a central
nucleus and myogenic regulatory factors will subsequently help to
migrate the nuclei toward the periphery to form a mature fibre
[11]. As such, the proportion of central nuclei has been used as
a marker of regenerative events within muscles [14,15]. Senescent
satellite cells are unable to enter this process and thus cannot
contribute to muscle tissue maintenance [16].
Progressive shortening of satellite cell telomeres plays a signifi-
cant role in their progression toward senescence thus contributing
to premature proliferative arrest and poor tissue renewal.
Telomeres are DNA–protein complexes (TTAGGG repeats)
located at the ends of every eukaryotic chromosomes, promoting
chromosomal and gene expression stability [17]. In the absence of
telomerase [18], telomeric length decreases after every division
cycle [19] because of the limitation of DNA polymerases in
completing replication of linear DNA strands. Once telomere
length reaches ,5 kbp, cells enter an irreversible state of arrested
growth and altered function, termed replicative senescence [19].
Even with slight telomerase activity in satellite cells [20],
premature telomere shortening has been reported in atrophying
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[21].
Considering that increased number of senescent satellite cells
can directly limit the regenerative potential of muscle tissue, we
speculated that the likelihood of finding senescent satellite cell in
vastus lateralis would be significantly higher in patients with COPD
and low muscle mass. To test this hypothesis, satellite cell and
central nuclei numbers as well as telomere length in limb muscle
specimens were quantified and compared between patients with
COPD with or without muscle atrophy and healthy subjects.
Materials and Methods
Ethics statement
The research protocol was approved by the institutional ethics
committee (Research ethics committee of the Institut universitaire de
cardiologie et de pneumologie de Que ´bec) and a signed informed consent
was obtained from each subject.
Subjects
Sixteen patients with Global Initiative for Chronic Obstructive
Lung Disease (GOLD) stage III and IV COPD and seven healthy
subjects with normal lung function, all males, were consecutively
recruited for this study. Based on a power of 80% and type I error
rate of 0.05 to find a significant difference of 3 central nuclei
between atrophied and non-atrophied patients, 7 patients per
group are needed. COPD diagnosis was based on a past smoking
history (.10 pack-year) and pulmonary function test showing
persistent airflow obstruction (forced expiratory volume in 1 s
[FEV1] ,50% of predicted value and FEV1/forced vital capacity
[FVC] ,70%) [22]. All patients with COPD were in a stable
condition at the time of the study and were neither suffering from
any other diseases nor using oral corticosteroids or any other
medication that could alter satellite cells behaviour. Because low
muscle mass is related to poor quality of life [23], reduced
functional capacity [7] or survival [8], patients with COPD were
subdivided based on the presence of muscle atrophy. In our study,
muscle atrophy was defined as mid-thigh cross-sectional area
(MTCSA) lower than 70 cm
2. MTCSA ,70 cm
2 has been
previously demonstrated to be associated with decreased survival
[8].
Pulmonary function, anthropometric measurements and
body composition
Standard pulmonary function tests including spirometry, lung
volumes, and carbon dioxide diffusion capacity were obtained in
all subjects during the initial evaluation according to previously
described guidelines [22]. Results were related to previously
published normal values [24]. Height and weight were measured
according to standardized methods [25]. Mid-thigh muscle cross-
sectional (MTCSA) area was determined using computed tomog-
raphy, as previously described [8].
Muscle biopsy
One needle biopsy of the vastus lateralis, performed as described
by Bergstro ¨m and routinely done in our laboratory [26] was
obtained in each participant. Muscle specimens were frozen in
liquid nitrogen and stored at 280uC for future analysis.
Immunofluorescence
Muscle section (10 mm) were fixed with ice-cold acetone and
methanol 60/40 (v/v) at 220uC for 20 minutes, washed with PBS,
incubated with a blocking solution (horse serum 1%) for 1 hour
and then incubated with the primary antibody overnight at 4uCi n
a humidified chamber. The primary antibody Pax-7, (R&D
Systems, Minneapolis, NE, USA) NCAM (R&D Systems) and
laminin (DAKO, Glostrup, Denmark) excesses were cleaned with
PBS, incubated with their specific secondary antibodies, a goat
anti-mouse Alexa FluorH 488 (R&D Systems) and a goat anti-
rabbit Alexa FluorH 546 (Invitrogen, Carlsbad, CA, USA) for
1 hour, washed with PBS and then incubated with DAPI for
15 minutes. Slides were analyzed and images were captured using
a Nikon Eclipse E600 microscope (Nikon Corporation). Immuno-
florescence were performed in duplicate on two distinct muscle
cryosections. To ensure maximal image quality, pictures were
taken within 24 hours after labelling. All the muscle samples where
labelled during the same experimentation.
Satellite cells and myonuclei labeling
To assess the number of satellite cells in muscle tissue,
immunofluorescence was used. Satellite cells have heterogeneous
expression of cellular markers resulting in a variety of subsets of
cell populations. Thus, it is recommended to use more than one
target to fully quantify satellite cells in a given sample [27]. Neural
cell adhesion molecules (NCAM) and the transcription factor
Pax7, two distinct proteins present in satellite cells, were used to
assess the satellite cell number. Immunofluorescence was per-
formed using a standard protocol against NCAM and Pax7 [27].
Laminin was used to delineate muscle fibres. Nuclei were labeled
using DAPI. Nuclei located deep to the basal lamina and positive
for NCAM or Pax7 were counted as satellite cells. The numbers of
satellite cells was counted over 100 myofibres and reported as the
number of satellite cells per 100 myofibres.
The presence of central nuclei was interpreted as a regenerative
event since myonuclei incorporation is a specific step of muscle
repair and satellite cells are responsible for 99% of muscle
regeneration [28]. A central nucleus was defined as a committed
cell being located inside the perimeter of the fibre delimited by
laminin. Number of central nuclei per 100 myofibres is reported.
Fibre typing and cross-sectional area
Muscle sections were stained using monoclonal anti-skeletal
myosin fast (Sigma, Oakville, ON, Canada) at 4uC with 1:200
dilution and VECTASTAIN Elite ABC system (Vector Labora-
tories, Burlington, ON, Canada). Peroxydase activity was detected
and muscle fibres were classified according to the staining
intensity: type I (non-stained) and type II (stained). All fibres were
counted with an image analysing system (Image Pro Plus 4.5 for
Windows, MediaCybernetics, Silver Spring, MD, USA) and
classified to obtain the fibre-type composition for each subject.
The mean muscle fibre cross-sectional area (CSA) was determined
for each fibre type. The fibre CSA was calculated based on 75
randomly selected fibres for each sample [29].
Genomic DNA extraction and Southern blot analysis
The intact genomic DNA extraction, digestion and migration
were performed as previously described [30]. The intact genomic
DNA obtained from muscle tissue was digested for 4 hours at
37uC in the presence of HinfI (0.2 units/ml) (New England Biolabs,
Ipswich, Massachussetts) to generate DNA fragment containing
telomere restriction fragments (TRFs). Three micrograms of
digested genomic DNA and DNA ladder (1 kb and high molecular
weight) were resolved by electrophoresis in 0,7% agarose gels that
were denatured and neutralized before the transfer on nylon
membrane. TRFs were detected by hybridization using a 32
P-
TTAGGG probe and visualized by autoradiography. The signal
responses were analyzed by Image J.
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The mean telomere length (L) was calculated by integrating the
signal intensity above background over entire TRFs distribution as
a function of TRFs length using the formula: L=S(ODiNLi)/
S(ODi) where ODi and Li are the signal intensity and TRF length
respectively at position L on the gel image. To determine the
minimum and maximum value of telomere length in a homoge-
nous way for all samples, the densitometric profile of TRF length
was integrated over the distance of migration: minimum and
maximum telomere length were corresponding to 5% and 95% of
this integration, respectively. Minimum, mean and maximum
telomere length values were determined for each sample from
three independent gels as previously published [31].
Signal analysis generated three distinct measurements that were
interpreted as follow: 1) minimal telomere length indicates the size
of telomere structures found in dividing cells such as satellite cells.
Thus, in satellite cells, shortening in minimal telomere length can
be interpreted as their replicative history [32]; 2) mean telomere
length represents the size of telomere structures in postmitotic
myonuclei which have been incorporated into muscle fibres from
birth to adulthood; 3) maximal telomere length is representative of
the size of native telomere length as found in skeletal muscle cells
[32]. Of these three measurements, a shorter minimal telomere
length in a given sample can be interpreted as a high likelihood of
finding a significant number of cells that have exhausted their
regenerative potential in this tissue.
Statistical analysis
Results are expressed as mean (6 SEM). All data were normally
distributed and statistical test performed accordingly. Differences
for all variables between the three groups were analyzed using
a one-way analysis of variance (ANOVA) except for telomere
length analyses for which one-way analysis of covariance
(ANCOVA) was performed to correct for age. Pearson linear
regression analysis was performed to test relationship between
variables. Differences were considered to be significant when
p,0.05.
Results
Subjects characteristics
Anthropometric characteristics and pulmonary function data
are provided in Table 1. Patients and healthy subjects did not
significantly differ regarding age and body mass index. Ten
patients had stage III, and the six remaining patients had stage IV
disease according to the GOLD classification. As previously
published, type I fibre distribution was significantly decreased in
patients with COPD. Type II fibre distribution followed the
reverse pattern as shown in Table 1. There was a significant
decrease in type I fibre CSA in the group of patient with COPD
and low muscle mass compared to controls and patients with
COPD and preserved muscle mass as shown in Table 1.
Satellite cell quantification
A representative vastus lateralis cryosections labeled for Pax7 and
laminin is depicted in Figure 1A. The number of Pax7+ and
NCAM+ satellite cells per 100 fibres did not differ between groups
(Figure 1B).
Central nucleus quantification
A representative cryosection labeled for nucleus and laminin is
provided in Figure 2A. The number of central nuclei averaged per
100 muscle fibres was higher in patients with COPD with
preserved muscle mass compared to patients with COPD and low
muscle mass and to controls (5.6462.95 vs 2.4761.17 vs
2.8661.58, respectively; p,0.05) (figure 2B).
Telomere length
Data for minimal, mean and maximal telomere lengths are
plotted in Figure 3. Minimal telomere length was significantly
shorter in patients with COPD and low muscle mass
(4479688 Kbp) compared to the other groups (COPD and
a (MTCSA .70 cm
2): 49386149 Kbp and controls:
51196123 Kbp; p,0.05). The mean telomere length was not
significantly different between patients with COPD ((MTCSA
.70 cm
2): 90526294 Kbp and (MTCSA ,70 cm
2):
86566177 Kbp; p.0.05) and controls (90546244 Kbp) even
after analysis considering MTCSA. The maximal telomere length
was significantly greater in controls (138466302 Kbp) compared
to patients with COPD ((MTCSA .70 cm
2): 128116277 Kbp
and (MTCSA ,70 cm
2): 126116197 Kbp; all p,0.05). Statisti-
cally significant correlations were found between minimal
(figure 4A), mean (figure 4B) and maximal (figure 4C) telomere
length with MTCSA (R=0.523, p=0.005, R=0.435, p=0.019
and R=0.491, p=0.009, respectively).
Discussion
One of the most striking systemic consequences of COPD is the
reduction in peripheral muscle mass resulting in muscle weakness,
decreased functional capacity and reduced survival [33,34].
Although several factors such as protein synthesis/degradation
imbalance, hypoxia, inactivity, inflammation, and oxidative stress
have been proposed to explain the initiation and the progression of
muscle wasting in COPD [35], the potential contribution of
impaired muscle regeneration has yet to be investigated. This was
done in the present study by evaluating satellite cell number,
occurrence of central nuclei and telomere length in peripheral
muscle tissue of individuals with or without COPD. One of the
major finding of this study is the significant decrease in minimal
telomere length observed in patients with COPD and muscle
atrophy compared to their COPD counterparts with better
preserved muscle mass and healthy subjects. This observation is
important because it suggests that the likelihood of finding
senescent satellite cells is increased in patients with severe COPD
and muscle atrophy. Supporting this assumption, presence of
shorter telomeres in muscle tissue was correlated with lower
MTCSA.
Satellite cells in COPD
Regeneration of muscle tissue in a given individual relies on
a sufficient number of competent satellite cells. As already shown,
the abundance of satellite cells in peripheral muscle of patients
with various degree of COPD had been demonstrated to be
invariable [36]. In support of this study, this relative preservation
in satellite cells number across these three groups as observed in
our study suggests that COPD has an insignificant impact on the
decline of the satellite cell population.
Despite the similar global satellite cells population in the 3 study
groups, the number of central nuclei, a surrogate for the number
of satellite cells engaged in a regenerative process, was significantly
increased in patients with COPD and a preserved muscle mass
compared to patients with COPD and muscle atrophy and to
subjects with normal lung function. These results suggest that an
accentuated number of regenerative events are taking place in the
muscle tissue of a subset of patients with COPD having a preserved
muscle mass. Similar results have been reported in diaphragm of
patients with COPD [37]. However, tissue renewal was likely
Telomere Shortening in COPD
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indicated by a reduced number of central nuclei in these
individuals compared to the other group of patient with COPD.
Discrepancies exist in the literature regarding the frequencies of
central nuclei in muscle tissue of patient with COPD. Decramer et
al. [14] has reported an increased number of central nuclei in
steroid-induced myopathy in patients with moderate-to-severe
COPD while Gosker et al. [15] did not find any difference
between patients with a moderate-to-severe COPD and controls.
This disparity could be attributed to the diversity of the population
Table 1. Subjects characteristics
Controls COPD COPD
(n=7) MTCSA .70 cm
2 MTCSA ,70 cm
2
(n=9) (n=7)
Age (years) 6762.7
a 6462.3
a 7061.7
a
BMI (kg/m
2) 27.261.7
a 27.261.8
a 22.361.7
b
FEV1,L 3.160.2
a 1.060.1
b 1.060.2
b*
FEV1, % predicted 107.363.4
a 34.062.5
b 31.465.8
b*
FVC, L 3.960.3
a 2.660.2
b 2.860.2
b{
FVC, % predicted 105.664.5
a 69.064.6
b 71.768.6
b
FEV1/FVC, % 79.361.5
a 36.661.3
c 33.163.9
c*
DLco, (ml CO/min/mmHG) 21.862.6
a 14.761.1
b 13.060.8
b{
MTCSA (cm
2) 103.567.8
a 85.563.3
b 66.465.5
c*
Type I fibre
Distribution, % 57.066.6
a 32.863.6
b 28.267.9
b
CSA, (mm
2) 52616360
a 47946364
a 42466314
b
Type II fibre
Distribution, % 43.066.6
a 67.263.6
b 71.867.9
b
CSA, (mm
2) 40266276 37316203 36776227
Definition of abbreviations: BMI=Body mass index; FEV1=Forced expiratory volume in 1 second; FVC=Forced vital capacity; DLCO=Diffusing capacity of carbon
monoxide; MTCSA=Mid-thigh cross-sectional area; CSA=Cross-sectional area. Values with different lower case letter are significantly different (p,0.05).
*p,0.001;
{p,0.01.
doi:10.1371/journal.pone.0039124.t001
Figure 1. Satellite cells quantification. A) Vastus lateralis muscle cryosections were labeled for co-expression and localization of nuclear Paired
box transcription factor 7 (green), DAPI (blue) and laminin (red). Cells positive for pax7 or NCAM (not shown) and DAPI located between the
plasmalemma and the basal lamina were counted as satellite cells (white arrow). The number of satellite cells is expressed over 100 fibres and
reported as a ratio. Ratio are calculated from 9 COPD and MTCSA .70 cm
2, 7 COPD and MTCSA ,70 cm
2 and 7 healthy subjects. B) The numbers of
nuclei having a positive label for Pax7 (white) and NCAM (black) were counted as satellite cells. Cells positive for pax7 or NCAM and DAPI located
between the plasmalemma and the basal lamina were counted as satellite cells. The number of satellite cells is expressed over 100 fibres and
reported as a ratio; ANOVA; p.0.05.
doi:10.1371/journal.pone.0039124.g001
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muscle dysfunction.
Telomere length and muscle tissue
Similar to other tissues, replication of satellite cells throughout
lifespan is marked by a progressive loss in telomere length defining
a finite number of replicative events in which these cells can be
engaged for muscle tissue regeneration [21]. For instance,
increased number of replicative events following repetitive
episodes of muscle injuries is paralleled by a faster telomere
shortening in muscle altered by dystrophic conditions. In
accordance, decreased telomere length was correlated with lower
proliferative capacity in cultured satellite cells from patients with
dystrophic muscles [38]. Telomere shortening in COPD has
already been reported in alveolar type II epithelial cells [39] and
blood leukocytes [40–42]. For the first time, the present report
extends this finding to muscle tissue in which shorter telomere
lengths was also found in patients with COPD when compared to
healthy subjects.
The minimal telomere length shortening seen in patients with
COPD and muscle atrophy is coherent with an increased satellite
cells proliferation history in this population. In response to tissue
damage, satellite cells increase their proliferation and are
incorporated to myofibres through a complex and highly regulated
myogenic program [11] a process during which the telomere
length is shortened. The specific prevalence of limb muscle tissue
injury throughout the progression of the COPD is unknown.
However, presence of central nuclei was markedly increased in
COPD with preserved MTCSA suggesting that, in this sub-
population of patients, the incidence of muscle damages resulting
in activation of muscle repair is higher. Eventually, this would lead
to the exhaustion of the replicative capacities of the satellite cells as
indicated by the reduction in telomere length and to the inability
to preserve muscle mass. The significant correlation between
minimal telomere length and MTCSA supports this assumption.
Besides an accelerated satellite cell replication, several bio-
chemical events may contribute to telomere shortening [43–45].
Because of its high guanine and cytosine content, a major target of
reactive oxygen species, telomeric DNA is more susceptible to
oxidative damage [46]. While most studies investigating the effects
of oxidative stress on telomere shortening are in vitro [47], an in vivo
link between oxidative stress and the rate of telomere shortening is
emerging [48,49]. During exercise, the production of reactive
oxygen species, such as superoxide anions, hydrogen peroxide, and
hydroxyl radicals is enhanced. Exercise is thus only be expected to
increase the rate of oxidative damage to DNA and other cellular
structures particularly when the capacity of the antioxidant
defence mechanisms is exceeded in COPD [50–53]. In COPD,
excessive oxidative stress has been reported in lower limb muscles
at rest, after exercise and also during disease exacerbation [52–54].
Additionally, the increased level of antioxidant activity observed
after exercise in healthy subjects is absent in patients with COPD
[50,55]. Thus, it is likely that accentuated oxidative stress, in
addition to higher replicative rate history, contributes to the
shortening of telomere length in muscle tissue of patients with
COPD as reported in the present study.
Methodological considerations
Despite a relatively modest sample size, a difference in telomere
length was observed between groups. The positive correlation
between telomere length and MTCSA is also reassuring about the
validity of the results. Southern blot was used instead of other
techniques such as PCR [41] to determine telomere length. This
was done because Southern blot is reliable and has the advantage
of providing three distinct length measurements that deliver
complementary information about the replicative history of the
cells. This methodology has also been extensively used in other
studies investigating muscle tissue telomere length [21,32].
Although telomere shortening was demonstrated, the mechanisms
involved in this phenomenon remain unresolved. Determination
of mechanisms and factors related to telomere shortening in
patients with COPD was beyond the scope of this study. Because
of the study design, analysis of the clinical relationship between
Figure 2. Central nucleus quantification. A) Cryosections were analyzed by labeling nuclei (blue) and laminin (red). Immuno-detection is shown
for 10 mm skeletal muscle cryosections. The number of central nuclei (white arrows) is expressed over 100 fibres and reported as a ratio. Ratio are
calculated from 9 COPD and MTCSA .70 cm
2, 7 COPD and MTCSA ,70 cm
2 and 7 healthy subjects. B) The total numbers of central nuclei were
quantified per 100 fibres for patients with COPD and MTCSA .70 cm
2, patients with COPD and MTCSA ,70 cm
2 and for healthy subjects. Nucleus
inside the perimeter of a given fibre delimited by laminin was counted as a central nucleus, expressed over 100 fibres and reported as a ratio. Distinct
letter represents a statistically significant difference (ANOVA; p,0.05).
doi:10.1371/journal.pone.0039124.g002
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should be addressed in subsequent studies.
Figure 3. Telomere length. A) Minimal, B) Mean and C) Maximal
telomere restriction fragment length of the vastus lateralis plotted in
healthy subjects (n=7), patients with COPD and MTCSA .70 cm
2)
(n=9) and patients with COPD and MTCSA ,70 cm
2 (n=7). The solid
horizontal line represents the mean value for the group. Distinct letter
represents a statistically significant difference (ANCOVA; p,0.05).
doi:10.1371/journal.pone.0039124.g003
Figure 4. Minimal, mean and maximum telomere length
correlation with MTCSA. A) Relationship between minimal telomere
length and Mid-thigh Cross-Sectional Area (MTCSA) in patients with
COPD and healthy controls. Telomere length significantly correlated
with MTCSA in the studied population (r=0.523; p=0.005). B)
Relationship between mean telomere length and Mid-thigh Cross-
Sectional Area (MTCSA) in patients with COPD and healthy controls.
Telomere length significantly correlated with MTCSA in the studied
population (r=0.435; p=0.019). C) Relationship between maximum
telomere length and Mid-thigh Cross-Sectional Area (MTCSA) in
Telomere Shortening in COPD
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Even if the number of satellite cells was constant throughout the
studied groups, the increased number of central nuclei observed is
suggestive of an accentuated repair process within the leg muscle
of patients with COPD and preserved muscle mass. An increase in
damage/repair recurrence may exhaust the regenerative capacity
of satellite cells leading to telomere shortening as exemplified by
a shorter minimal telomere length in patients with COPD and
muscle atrophy. Further studies on the intrinsic capacity of satellite
cells to replicate and adopt a myogenic development are needed.
Better understanding of the biological behaviour of satellite cells in
COPD will be instrumental in designing pharmacological and
exercise training interventions aimed at improving or maintaining
muscle mass in this disease.
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